Litigation Details for CORCEPT THERAPEUTICS, INC. v. SUN PHARMA GLOBAL FZE (D.N.J. 2019)
✉ Email this page to a colleague
CORCEPT THERAPEUTICS, INC. v. SUN PHARMA GLOBAL FZE (D.N.J. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-07-22 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-06-17 |
| Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Parties | SUN PHARMA GLOBAL FZE | ||
| Patents | 10,195,214; 10,500,216; 8,921,348; 9,829,495 | ||
| Attorneys | CHARLES MICHAEL LIZZA | ||
| Firms | Rivkin Radler LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. SUN PHARMA GLOBAL FZE
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for CORCEPT THERAPEUTICS, INC. v. SUN PHARMA GLOBAL FZE (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-07-22 | 1 | Complaint | of United States Patent Nos. 8,921,348 (“the ʼ348 Patent”),10,195,214 (“the ʼ214 Patent”), and 9,829,495… States Patent (10) Patent No.: US 10,195,214 B2 … US 10,195,214 B2 … Feb.5,2019 US 10,195,214 B2 … US 10,195,214 B2 1 | External link to document |
| 2020-01-22 | 33 | Amended Complaint | of United States Patent Nos. 8,921,348 (“the ʼ348 Patent”),10,195,214 (“the ʼ214 Patent”), 9,829,495 … States Patent (10) Patent No.: US 10,195,214 B2 … US 10,195,214 B2 … Feb.5,2019 US 10,195,214 B2 … US 10,195,214 B2 1 | External link to document |
| 2020-01-27 | 35 | Order | infringement of an additional patent, U.S. Patent No. 10,500,216 (the "'216 Patent") (D.I. 33). …adjustments to the case schedule to incorporate the new patent-in-suit into this case: …2020 Answer to Complaint ('216 Patent) February 10, 2020… Reply to Counterclaims ('216 Patent) February 10, 2020… ('216 Patent) January 23, 2020 February 24, 2020 | External link to document |
| 2020-01-30 | 36 | Answer to Amended Complaint | United States Patent Nos. 8,921,348 (“the ʼ348 Patent”),10,195,214 (“the ʼ214 Patent”), and 9,829,495…the ʼ348, ʼ495, 10,195,214 (“the ʼ214 Patent”) and 10,500,216 (“the ‘216 Patent”) patents (together, “…expiration of the ʼ348 Patent, the ʼ214 Patent, the ʼ495 Patent and the ‘216 Patent. Defendants deny any…9,829,495 (“the ʼ495 Patent”) and 10,500,216 (“the ’216 patent”) (together, “the patents-in-suit”), owned …claim of U.S. Patent Nos. 8,921,348 (“the ʼ348 Patent”) and 9,829,495 (“the ʼ495 Patent”), and that each | External link to document |
| 2021-05-26 | 64 | Amended Complaint | Exhibit A - US 8,921,348., # 2 Exhibit B - US 10,195,214, # 3 Exhibit C - US 9,829,495, # 4 Exhibit D … AMENDED COMPLAINT Second Amended Complaint for Patent Infringement against SUN PHARMA GLOBAL FZE, SUN…2019 17 June 2021 2:19-cv-15678 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-06-16 | 66 | Letter | certain claims of United States Patent Nos. 8,921,348, 9,829,495; 10,195,214; 10,500,216; 10,842,800; and…Court has subject matter jurisdiction over this patent infringement action (the “Action”). This Court…and 10,842,801 (together, the “Asserted Patents”) in connection with Sun’s submission of Abbreviated … 2. Until expiration of the Asserted Patents, including any extensions and pediatric exclusivities…assigns, is enjoined from infringing the Asserted Patents, on its own part or through any third party on | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
